Open Access

Peritonitis-induced peritoneal injury models for research in peritoneal dialysis review of infectious and non-infectious models

  • Yasuhiko Ito1Email author,
  • Hiroshi Kinashi1, 2,
  • Takayuki Katsuno1,
  • Yasuhiro Suzuki1 and
  • Masashi Mizuno1
Renal Replacement Therapy20173:16

DOI: 10.1186/s41100-017-0100-4

Received: 10 January 2017

Accepted: 9 February 2017

Published: 1 May 2017

Abstract

Peritonitis is an important complication of peritoneal dialysis. Several animal peritonitis models have been described, including bacterial and fungal models that are useful for studying inflammation in peritonitis. However, these models have limitations for investigating peritoneal fibrosis induced by acute inflammation and present difficulties in handling the infected animals. Animal models of peritonitis which induced peritoneal fibrosis are important for establishing new therapies to improve peritoneal damage induced by peritonitis. Here, we present an overview of representative animal models of peritoneal dialysis-associated infectious and non-infectious peritonitis, including our novel animal models (scraping and zymosan models) that mimic peritoneal injury associated with fibrosis and neoangiogenesis caused by bacterial or fungal peritonitis.

Keywords

Peritonitis Non-infectious peritonitis model Scraping model Zymosan model

Background

There are several reasons why peritonitis is important in peritoneal dialysis (PD) treatment. First, peritonitis remains an important cause of death in PD patients. The mortality rate for peritonitis is approximately 3% [1, 2], and peritonitis is a contributing cause of death in more than 10% of PD patients [3]. Second, peritonitis remains an important factor in withdrawal from PD. In the PD registry of the Nagoya group from both 2005 to 2007 [4] and 2010 to 2012 [5], the most common reasons for withdrawal from PD have been PD-related peritonitis, followed by dialysis failure/ultrafiltration failure and social problems such as lack of family support. PD peritonitis is primarily caused by gram-positive organisms that typically result from touch contamination. The mean incidence of peritonitis as reported twice from a study over a 3-year period was one episode every 42.8 [4] and 47.3 [5] patient-months. Third, peritonitis presents a risk for the development of encapsulating peritoneal sclerosis (EPS) [6]. The duration of peritonitis is independently associated with EPS [7]. In particular, fungal and Pseudomonas infections put patients at a higher risk for the development of EPS [8]. Fourth, peritonitis is one of the risks for a decrease in residual renal function. The number of peritonitis episodes has been reported to be an independent predictor of the development of anuria [9]. Fifth, peritonitis is an important cause of peritoneal membrane injury, which leads to peritoneal fibrosis, neoangiogenesis, and peritoneal dysfunction [10].

The characteristic features of chronic peritoneal damage in PD treatment are the loss of ultrafiltration capacity associated with morphological submesothelial fibrosis with extracellular matrix accumulation, and neoangiogenesis. The pathogenesis of peritoneal fibrosis is attributed to a combination of bioincompatible factors in PD fluid (PDF) and peritonitis, especially repeated episodes of peritonitis [11]. We have reported that uremia is associated with inflammation of the peritoneal membrane [12]. Histologically, acute peritonitis can cause morphological damage to the peritoneum [10, 13]. Detachment and disintegration of mesothelial cells is observed, along with the appearance of fibrin exudation and numerous infiltrating cells, ultimately resulting in internal structures becoming unrecognizable [6]. Therefore, peritonitis plays a crucial role in the development of peritoneal damage leading to peritoneal membrane failure.

Animal models of peritonitis-induced peritoneal fibrosis are important for establishing new therapies to improve peritoneal damage induced by peritonitis.

Peritonitis models induced by bacteria or fungus

There are several reports of animal models of peritonitis induced by bacteria or fungi (Table 1). The pathogenic microorganisms used to induce peritonitis include Staphylococcus aureus [1418], Staphylococcus epidermidis [19, 20], Pseudomonas aeruginosa [21], and Candida albicans [22]. These models of infectious peritonitis have been mainly used to elucidate the mechanism of inflammation in the membrane and the mechanism of acute peritoneal membrane failure. However, the acute peritonitis model is not typically used to study peritoneal fibrosis.
Table 1

Summary of representative rodent models used to study peritoneal dialysis and its associated complications

Representative animal models

 

Methods

Species

Experimental period

Peritoneal dysfunction

Neoangiogenesis

Fibrosis

EPS

References

Peritonitis model

         

Infectious model

Bacteria

Staphylococcus aureus

Mouse

2 days

No report

No report

No report

[14]

Rat

2 weeks

No report

No report

±

[1518]

  

Staphylococcus epidermidis

Mouse

2 weeks

No report

No report

No report

[20]

  

Pseudomonas aeruginosa

Rat

1 week

No report

No report

No report

[21]

 

Fungus

Candida albicans

Mouse

1 day

No report

No report

No report

[22]

 

Performance without aseptic precautions

 

Mouse

1 week

+

+

No report

[23]

Rat

1 week

+

+

No report

[2325]

Non-infectious model

 

LPS

Mouse

1 day

+

No report

No report

[26, 27]

Rat

1 day

+

No report

No report

[28, 29]

  

PDF with LPS

Rat

3–6 weeks

+

+

+

[2936]

  

SES

Mouse

2 days

No report

No report

No report

[11, 37]

  

Scraping

Rat

2 weeks

+

+

+

[38, 39]

  

Zymosan with scraping

Rat

5 weeks

No report

+

+

±

[64, 67]

  

PDF

Mouse

4–5 weeks

+

+

+

[7883]

Rat

1–20 weeks

+

+

+

[6977]

  

Chlorhexidine

Mouse

1–8 weeks

+

+

+

+

[97108]

Rat

1–8 weeks

+

+

+

+

[8496]

  

Methylglyoxal

Mouse

3–7 weeks

+

+

+

+

[113, 114]

Rat

3 weeks

+

+

+

+

[109112]

  

TGF-β1

Mouse

1–10 weeks

No report

+

+

+

[115118]

Rat

1–4 weeks

+

+

+

[119, 120]

LPS lipopolysaccharide, PDF peritoneal dialysis fluid, SES a lyophilized cell-free supernatant, TGF-β1 transforming growth factor-β1, EPS encapsulating peritoneal sclerosis

A catheter-induced model of gram-positive bacterial peritonitis has been developed, which is an acute bacterial peritonitis model with bacteria originating from skin flora due to lack of aseptic precautions [2325]. In subsequent studies, these researchers used a model of lipopolysaccharide (LPS)-induced peritonitis instead of the gram-positive bacteria-induced peritonitis model [26, 27]. They investigated the role of nitric oxide (NO) released by endothelial NO synthase (eNOS) in the gram-positive bacterial peritonitis model [23] and the LPS-induced peritonitis model [27] and suggested that the selective inhibition of eNOS might ameliorate the poor peritoneal function caused by acute peritonitis. They reported that mice injected with LPS developed a cloudy dialysate with increased white blood cell counts and NO metabolite levels and inflammatory cell infiltration in the peritoneum. These observations are similar to those of the gram-positive peritonitis model.

The mechanisms of inflammation were studied in the bacterial and fungal peritonitis models; however, these models were not used to investigate the long-term complications such as fibrosis and neoangiogenesis.

Non-infectious peritonitis models

Currently, the number of reports in which investigators use the non-infectious peritonitis model is increasing. The non-infectious model is convenient and useful for handling animals and performing experiments. We suggest that a model of peritoneal fibrosis induced in a peritonitis model will help identify new strategies for preventing peritoneal fibrosis. Many studies have used the LPS-induced peritoneal injury model [2636]. LPS derived from Escherichia coli (Sigma, St. Louis, MO) is frequently used [2630, 33, 35]. A method involving a single LPS dose was used to study peritoneal inflammation and dysfunction [2629]. Rat peritoneal inflammation and significant changes in neoangiogenesis were caused by daily administration of PDF over 3 weeks following an initial exposure to LPS [2935].

Another non-infectious peritonitis model induced by administration of lyophilized cell-free supernatants from Staphylococcus epidermidis has been used to study the regulation of inflammation and leukocyte trafficking [11, 37]. Hurst et al. showed that interleukin-6 (IL-6)/soluble IL-6 receptor trans-signaling, which involves signal transducer and activator of transcription 3 (STAT3) activation, regulates chemokine secretion and polymorphonuclear neutrophil apoptosis in the peritoneal cavity. These mechanisms of inflammation and leukocyte trafficking have been clearly shown in the non-infectious model.

Here, we introduce a model of peritoneal fibrosis that we generated in rats and mice that is induced by acute inflammation with mechanical scraping, the so-called “scraping model.”

Scraping model

We first reported the scraping model as a non-infectious, peritonitis-induced peritoneal fibrosis model [38]. After opening the rat abdomen under anesthesia, the right parietal peritoneum received hand-driven scratching for 1 min using the edge of a 15-ml centrifuge tube (Fig. 1). Rats freely consumed food with or without NaCl loading after surgery [3840]. Similarly, in mice, the right parietal peritoneum was scraped for 90 s with the cap of an injection needle.
Fig. 1

Procedures to generate scraping model. Used by permission from Methods Mol Biol [40]

In this model (Fig. 2), neutrophil infiltration with fibrin exudation from the scraped peritoneum was demonstrated in 6 to 24 h after surgery. The predominant infiltrating cells switched to a mononuclear population on day 3, and inflammation gradually decreased thereafter. From days 7 to 14, the peritoneum became markedly thickened with the accumulation of alpha-smooth muscle actin (α-SMA)-positive fibroblasts and type III collagen. Mesothelial cells were not detected in 6 to 24 h after scraping, while approximately 30 and 70% of the total peritoneal length was covered with mesothelial cells on days 3 and 14, respectively. Increased CD31-positive blood vessel density was observed, which peaked at day 14. Transforming growth factor-β (TGF-β) and plasminogen activator inhibitor-1 (PAI-1), mainly expressed in the submesothelial compact zone, increased rapidly starting on day 3 and peaked at day 14. TGF-β and PAI-1 messenger RNA (mRNA) expression was upregulated from day 3 and peaked at day 7. In contrast, monocyte chemotactic protein-1 (MCP-1) mRNA rapidly increased and peaked at day 3. The pathology of this model in the early stage is characterized by strong infiltration of neutrophils and macrophages. The latter stage of this model is characterized by fibrosis and neoangiogenesis. In addition, peritoneal membrane permeability increased in rats that underwent bilateral scraping [38]. The pathological features and time course of this model are summarized in Figs. 2 and 3a.
Fig. 2

Pathological findings of rat scraping model. Used by permission from Am J Physiology [38]

Fig. 3

Time course of rat scrape model (a) and zymosan-induced fungal peritonitis model (b)

Using this model, we investigated the effects of mineralocorticoid receptor (MR) blockade with salt loading [38]. The local renin-angiotensin-aldosterone system (RAAS) is thought to play a role in peritoneal injury in PD patients [41]. Peritoneal mesothelial cells have been observed to express angiotensinogen, angiotensin-converting enzyme (ACE), and angiotensin II type 1 receptors (AT1R) [42, 43]. We found that MRs were expressed by rat fibroblasts and scraped peritoneum. Treatment with spironolactone suppressed macrophage infiltration, neoangiogenesis, and fibrosis, which is associated with the suppression of TGF-β and PAI-1 expression, thereby resulting in improvement of peritoneal dysfunction, including ultrafiltration, glucose transport, and albumin leakage [38]. The effects of spironolactone have also been shown in the LPS-induced peritoneal injury model [36].

In addition, we demonstrated the effects of atrial natriuretic peptide (ANP) in this model [39]. ANP has been used as a diuretic and vasodilator in clinical settings. ANP has been shown to play an important function in the inhibition of RAAS [44, 45]. ANP and brain natriuretic peptide (BNP) have been reported to prevent cardiac fibrosis [44, 46] and renal fibrosis [4749], and to reduce infarct size in acute myocardial infarction [50]. We demonstrated that AT1R, ACE, and atrial natriuretic peptide receptor (NPR-A) mRNA expression were increased and peaked at days 14, 7, and 7, respectively. ANP administration resulted in a significant reduction in macrophage infiltration, fibrosis, and neoangiogenesis [39]. In this model, the salt loading progression of peritoneal fibrosis is likely to be involved in local RAAS activation. Administration of an MR blocker or ANP with antibiotics may prevent peritoneal membrane dysfunction associated with fibrosis and neoangiogenesis in human bacterial peritonitis. In a small study, 25 mg/day of spironolactone for 6 months was shown to reduce CD20 and collagen IV levels in the human peritoneal membrane [51]. Recently, the scraping model was used to study the effectiveness of cell therapy using the mesothelial cells to prevent peritoneal damage in PD patients [52].

Zymosan-induced fungal peritonitis model

By modifying the scraping model, we established the zymosan-induced fungal peritonitis model. Although fungal peritonitis is not common, yeast infection with the most common Candida species results in a poor outcome with high mortality [5355]. The 2016 International Society for Peritoneal Dialysis guidelines recommends removal of the PD catheter in fungal peritonitis [56]. Several clinical observations have suggested that EPS could be induced by a single occurrence of fungal peritonitis [5660]. The cell walls of many types of yeast activate various signaling reactions, including the complement system [61]. Complement maintains host homeostasis by eliminating microorganisms and irregular cells and also regulates cellular immunity. The complement system in the peritoneum is continuously active at low levels, and complement regulators (CRegs) regulate complement activation. Irregular activation of complement leads to tissue damage in many diseases [62, 63].

We demonstrated the expression of CRegs, Crry, CD55, and CD59 in rat peritoneum, especially along the mesothelial cell layer [64]. In rat peritoneum, combined blockade of Crry and CD59 induced severe focal inflammation with edema [65]. We examined the state of complement activation in the aforementioned rat scraping model, and C3 and C3b were transiently present in the inflammatory stage at day 3 [64]. Zymosan is abundant in the cell walls of fungi and activates the complement system through the alternative pathway [66].

We demonstrated that administration of zymosan after scraping promoted severe peritoneal injury that is pathologically similar to human fungal peritonitis. Zymosan (5 mg/rat/day, 2 mg/mouse/day) mixed with PDF was intraperitoneally injected into the rat or mouse abdominal cavity for up to 5 days after scraping the rat or mouse peritoneum [40, 64, 67]. Macroscopic findings in the zymosan rats showed the presence of a few white plaques at day 3, and yellow-white plaques at day 5, while no plaques were found in the control scraping model. Plaque fusion resulted in the formation of a yellow-white sheet covering the peritoneum with numerous small vessels running into the plaques, which suggests the occurrence of peritoneal neovascularization in the zymosan model at day 5. Peritoneal thickening associated with severe infiltration of inflammatory cells continued and remained present in the zymosan model at day 36, while the peritoneum was of normal appearance in the control scraping rats.

In recent experiments, we found that disease severity was affected by the lots of the zymosan (Sigma-Aldrich, St. Louis, MO). Expression of CRegs, Crry, CD55, and CD59 transiently decreased in the control scraping model at day 5. In contrast, CRegs expression was further decreased in the zymosan model at day 5 and continued decreasing up to day 18. Complement activation products, C3b and membrane attack complex (MAC), were clearly found in the zymosan model from days 1 to 5, and small amounts of these products remained at days 18 and 36. The time course of this model is summarized in Fig. 3b.

Systemic complement depletion by cobra venom factor or local suppression of complement activation by Crry-immunoglobulin or soluble complement receptor 1 dramatically reduced complement activation, peritoneal thickening, and inflammation. These findings clearly indicated that the zymosan model is a complement-dependent model of severe proliferative peritonitis [64]. Fungal peritonitis is known to be one of the causes of EPS. Subsequently, we successfully demonstrated that further enhancement of complement activation by inhibiting CRegs and enhancing systemic activation with cobra venom factor in the zymosan model induced fibrin exudation, which is the initial event of EPS [68].

Other models of non-infectious peritoneal injury associated with inflammation and fibrosis

Administration of PDF into the abdominal cavity of rats and mice by repeated intraperitoneal injection or implanting a catheter is a method used to study the pathophysiological changes of the peritoneum associated with PD [6983], but a non-peritonitis model. Daily intraperitoneal injection of 4.25% glucose dialysate into the rat abdominal cavity for 1 week induced an increased peritoneal membrane transport rate and the absence of the peritoneal surface layer, as observed by electron microscopy [69, 70]. Daily injection of PDF (100 ml/kg, once or twice daily) was performed for up to 8 or 12 weeks to obtain morphological changes in the rat peritoneum [7173]. Implantation of a silicon catheter into the rat abdomen was reported to amplify peritoneal inflammation from PDF through a foreign body reaction [74]. However, the peritoneum of rats that received only a puncture without infusion of any solution showed no functional or pathological changes [73, 75].

A model of renal insufficiency, such as 5/6 nephrectomy, was used in combination with PDF infusion to closely model the clinical situation of peritoneal dialysis patients and to understand the influence of PD on residual renal function [76, 77]. Daily intraperitoneal exposure of 1.5–3.0 ml of 4.25% glucose PDF for 4 or 5 weeks, with or without implanting a catheter, produced peritoneal dysfunction and morphological changes, such as fibrosis and neoangiogenesis, in mice [7883].

Chronic intraperitoneal exposure to chemical irritation (chlorhexidine gluconate (CG)) is used as an experimental model of peritoneal fibrosis with inflammation and EPS. Suga et al. developed a CG-induced peritoneal fibrosis model in rats [84]. Daily injection of 0.1% CG in 15% ethanol, dissolved in 2–3 ml saline per 200 g body weight, was administered in the rat peritoneal cavity [8587]. At day 7, the peritoneal tissue was partially thickened with edema and showed initial accumulation of connective tissues and modest cell migration. At day 14, significant alterations were found, including peritoneal thickening with edema, cell infiltration, and neoangiogenesis. At days 21 to 28, the peritoneal tissue was markedly thickened and showed remarkable proliferation of collagen fibers. The number of macrophages gradually increased in the thickened areas and reached a maximum at day 21. At day 28, neoangiogenesis had decreased, whereas collagen fibrils had accumulated. At day 35, fibrillary elements with cell infiltration occupied the submesothelial zone. Peritoneal resting for 3 weeks after 3 weeks of CG exposure ameliorated some functional parameters in the peritoneum; however, elevated peritoneal thickness and fibrosis continued during the resting period [8891]. Placing an infusion pump in the rat abdominal cavity was reported as an alternative administration route for CG [9294].

A lower dosage of CG is an option for producing mild peritoneal injury [95, 96]. Mice were given daily intraperitoneal administration of 0.3 ml or 10 ml saline/kg body weight containing 0.1% CG in 15% ethanol [97, 98]. Peritoneal fibrosis and increased infiltration of mononuclear cells were observed over time. Peritoneal fibrosis reached the chronic inflammatory stage, and macroscopic evidence of EPS was observed by 8 weeks. Lower doses of CG or shorter time courses produced milder and more infrequent development of peritoneal fibrosis [99, 100]. Recent studies showed that a standard peritoneal fibrosis model could be produced in mice following treatment with 0.1% CG every other day or three times a week for 1–3 weeks [101108].

Glucose degradation products contained in PDF contribute to the biocompatibility of conventional PDF and are risk factors for EPS. Methylglyoxal (MGO) is an extremely toxic glucose degradation product, and administration of PDF containing MGO can be used as an animal peritoneal fibrosis model. Rats were given intraperitoneal injections of 100 ml/kg of 2.5% glucose PDF (pH 5.0) containing 20 mM MGO every day for 3 weeks [109111]. Peritoneal function decreased significantly, and fibrous peritoneal thickening with proliferation of mesenchymal-like mesothelial cells and abdominal cocoon was induced. The combination of low doses of MGO and adenine-induced renal failure accelerated the progression of fibrous peritoneal thickening, whereas both MGO and renal failure alone did not [112]. Intraperitoneal injection of PDF (100 ml/kg) containing 20 or 40 mM MGO for five consecutive days per week for 3 weeks induced peritoneal injury in mice [113, 114]. We clearly showed the presence of severe lymphangiogenesis in the diaphragm of both CG and MGO models [96, 114]. TGF-β is a central mediator of peritoneal fibrosis. Overexpression of TGF-β1 driven by intraperitoneal adenovirus administration induced peritoneal fibrosis through epithelial mesenchymal transition, neoangiogenesis, and poor peritoneal function in mice [115118] and rats [119, 120]. Other chemical irritants, such as deoxycholate [121], household bleach [122] and acidic solutions [123], were also reported to produce peritoneal inflammation, fibrosis, and abdominal cocoon in rats.

Conclusions

Non-infectious peritonitis models are convenient and useful for animal handling and performing experiments. The peritoneum in the scraping model showed signs of peritonitis initially and fibrosis at a later stage. These pathological changes, along with alterations in solute transport, mimic those observed in bacterial peritonitis. This model is useful for exploring strategies for the treatment and prevention of peritoneal fibrosis and membrane failure. The zymosan model is useful for studying the mechanisms of fungal peritonitis and the drugs used to reduce peritoneal damage induced by fungal peritonitis. Anti-complement therapy might be useful as a therapeutic in human fungal peritonitis and related peritoneal damage. Other non-infectious models, such as CG and MGO models, are also useful for investigating the pathophysiology of fibrosis with inflammation, angiogenesis, and lymphangiogenesis.

Abbreviations

ACE: 

Angiotensin-converting enzyme

ANP: 

Atrial natriuretic peptide

AT1R: 

Angiotensin II type 1 receptors

BNP: 

Brain natriuretic peptide

CG: 

Chlorhexidine gluconate

CRegs: 

Complement regulators

eNOS: 

Endothelial NO synthase

IL-6: 

Interleukin-6

LPS: 

Lipopolysaccharide

MAC: 

Membrane attack complex

MCP-1: 

Monocyte chemotactic protein-1

MGO: 

Methylglyoxal

MR: 

Mineralocorticoid receptor

NO: 

Nitric oxide

NPR-A: 

Natriuretic peptide receptor

PD: 

Peritoneal dialysis

PDF: 

PD fluid

RAAS: 

Renin-angiotensin-aldosterone system

STAT3: 

Signal transducer and activator of transcription 3

TGF-β: 

Transforming growth factor-β

α-SMA: 

Alpha-smooth muscle actin

Declarations

Acknowledgements

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (YI, # 20590972).

Funding

There is no funding. The authors declare that no financial conflict of interest exists.

Availability of data and materials

Figures 1 and 2 were used under permission from Methods Mol Biol [40] and Am J Physiology [38].

Authors’ contributions

YI and HK planned the study, searched and collected the literatures, and wrote the manuscript. All the authors wrote the manuscript partly. TK, YS, and MM discussed the contents of the manuscript with YI and HK. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine
(2)
Department of Pathology, University Medical Center Utrecht

References

  1. Brown MC, Simpson K, Kerssens JJ, Mactier RA, Scottish Renal Registry. Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000–2007). Perit Dial Int. 2011;31:639–50.PubMedView ArticleGoogle Scholar
  2. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002–2003. Perit Dial Int. 2009;29:297–302.PubMedGoogle Scholar
  3. Pajek J, Hutchison AJ, Bhutani S, Brenchley PE, Hurst H, Perme MP, et al. Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis. Perit Dial Int. 2014;34:289–98.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Mizuno M, Ito Y, Tanaka A, Suzuki Y, Hiramatsu H, Watanabe M, et al. Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin Exp Nephrol. 2011;15:727–37.PubMedView ArticleGoogle Scholar
  5. Mizuno M, Ito Y, Suzuki Y, Sakata F, Saka Y, Hiramatsu T, et al. Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry. Clin Exp Nephrol. 2016;20:960–97.PubMedView ArticleGoogle Scholar
  6. Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, et al. Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients. PLoS One. 2016;11:e0154644.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Nakao M, Yokoyama K, Yamamoto I, Matsuo N, Tanno Y, Ohkido I, et al. Risk factors for encapsulating peritoneal sclerosis in long-term peritoneal dialysis: a retrospective observational study. Ther Apher Dial. 2014;18:68–73.PubMedView ArticleGoogle Scholar
  8. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int. 2005;25(Suppl 4):S14–8.PubMedGoogle Scholar
  9. Szeto CC, Kwan BC, Chow KM, Chung S, Yu V, Cheng PM, et al. Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 2015;35:180–8.PubMedView ArticleGoogle Scholar
  10. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.PubMedGoogle Scholar
  11. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010;21:1077–85.PubMedView ArticleGoogle Scholar
  12. Sawai A, Ito Y, Mizuno M, Suzuki Y, Toda S, Ito I, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26:2322–32.PubMedView ArticleGoogle Scholar
  13. Verger C, Luger A, Moore HL, Nolph KD. Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. Kidney Int. 1983;23:823–31.PubMedView ArticleGoogle Scholar
  14. Catalan MP, Esteban J, Subirá D, Egido J, Ortiz A, Grupo de Estudios Peritoneales de Madrid-FRIAT/IRSIN. Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int. 2003;23:123–6.PubMedGoogle Scholar
  15. Calame W, Afram C, Blijleven N, Hendrickx RJ, Namavar F, Beelen RH. Establishing an experimental infection model for peritoneal dialysis: effect of inoculum and volume. Perit Dial Int. 1993;13(Suppl 2):S79–80.PubMedGoogle Scholar
  16. Welten AG, Zareie M, van den Born J, ter Wee PM, Schalkwijk CG, Driesprong BA, et al. In vitro and in vivo models for peritonitis demonstrate unchanged neutrophil migration after exposure to dialysis fluids. Nephrol Dial Transplant. 2004;19:831–9.PubMedView ArticleGoogle Scholar
  17. van Westrhenen R, Westra WM, van den Born J, Krediet RT, Keuning ED, Hiralall J, et al. Alpha-2-macroglobulin and albumin are useful serum proteins to detect subclinical peritonitis in the rat. Perit Dial Int. 2006;26:101–7.PubMedGoogle Scholar
  18. Akman S, Koyun M, Gelen T, Coskun M. Comparison of intraperitoneal antithrombin III and heparin in experimental peritonitis. Pediatr Nephrol. 2008;23:1327–30.PubMedView ArticleGoogle Scholar
  19. Mactier RA, Moore H, Khanna R, Shah J. Effect of peritonitis on insulin and glucose absorption during peritoneal dialysis in diabetic rats. Nephron. 1990;54:240–4.PubMedView ArticleGoogle Scholar
  20. Gallimore B, Gagnon RF, Richards GK. Response of chronic renal failure mice to peritoneal Staphylococcus epidermidis challenge: impact of repeated peritoneal instillation of dialysis solution. Am J Kidney Dis. 1989;14:184–95.PubMedView ArticleGoogle Scholar
  21. Finelli A, Burrows LL, DiCosmo FA, DiTizio V, Sinnadurai S, Oreopoulos DG, et al. Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Perit Dial Int. 2002;22:27–31.PubMedGoogle Scholar
  22. Kretschmar M, Hube B, Bertsch T, Sanglard D, Merker R, Schröder M, et al. Germ tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect Immun. 1999;67:6637–42.PubMedPubMed CentralGoogle Scholar
  23. Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol. 2003;14:3205–16.PubMedView ArticleGoogle Scholar
  24. Combet S, Van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, et al. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol. 1999;10:2185–96.PubMedGoogle Scholar
  25. Ferrier ML, Combet S, van Landschoot M, Stoenoiu MS, Cnops Y, Lameire N, et al. Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int. 2001;60:2343–50.PubMedView ArticleGoogle Scholar
  26. Ni J, Cnops Y, McLoughlin RM, Topley N, Devuyst O. Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int. 2005;25(Suppl 3):S11–4.PubMedGoogle Scholar
  27. Ni J, McLoughlin RM, Brodovitch A, Moulin P, Brouckaert P, Casadei B, et al. Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant. 2010;25:86–96.PubMedView ArticleGoogle Scholar
  28. Breborowicz A, Połubinska A, Wu G, Tam P, Oreopoulos DG. N-acetylglucosamine reduces inflammatory response during acute peritonitis in uremic rats. Blood Purif. 2006;24:274–81.PubMedView ArticleGoogle Scholar
  29. Korybalska K, Wieczorowska-Tobis K, Polubinska A, Wisniewska J, Moberly J, Martis L, et al. L-2-oxothiazolidine-4-carboxylate: an agent that modulates lipopolysaccharide-induced peritonitis in rats. Perit Dial Int. 2002;22:293–300.PubMedGoogle Scholar
  30. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, et al. Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int. 1999;19(Suppl 2):S384–7.PubMedGoogle Scholar
  31. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int. 2001;21(Suppl 3):S368–72.PubMedGoogle Scholar
  32. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol. 2002;13:721–8.PubMedGoogle Scholar
  33. Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int. 2004;24:115–22.PubMedGoogle Scholar
  34. Nie J, Hao W, Dou X, Wang X, Luo N, Lan HY, et al. Effects of Smad7 overexpression on peritoneal inflammation in a rat peritoneal dialysis model. Perit Dial Int. 2007;27:580–8.PubMedGoogle Scholar
  35. Song SH, Kwak IS, Yang BY, Lee DW, Lee SB, Lee MY. Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model. Nephrology (Carlton). 2009;14:155–63.View ArticleGoogle Scholar
  36. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest. 2014;94:839–50.PubMedView ArticleGoogle Scholar
  37. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705–14.PubMedView ArticleGoogle Scholar
  38. Nishimura H, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S, et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 2008;294:F1084–93.PubMedView ArticleGoogle Scholar
  39. Kato H, Mizuno T, Mizuno M, Sawai A, Suzuki Y, Kinashi H, et al. Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model. Nephrol Dial Transplant. 2012;27:526–36.PubMedView ArticleGoogle Scholar
  40. Mizuno M, Ito Y. Rat models of acute and/or chronic peritoneal injuries including peritoneal fibrosis and peritoneal dialysis complications. Methods Mol Biol. 2016;1397:35–43.PubMedView ArticleGoogle Scholar
  41. Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int. 2010;78:23–8.PubMedView ArticleGoogle Scholar
  42. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005;25:38–47.PubMedGoogle Scholar
  43. Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 2005;67:1126–35.PubMedView ArticleGoogle Scholar
  44. Tsuneyoshi H, Nishina T, Nomoto T, Kanemitsu H, Kawakami R, Unimonh O, et al. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation. 2004;110(11 Suppl 1):II174–9.PubMedGoogle Scholar
  45. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008;29:1485–94.PubMedView ArticleGoogle Scholar
  46. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation. 2003;107:807–10.PubMedView ArticleGoogle Scholar
  47. Kasahara M, Mukoyama M, Sugawara A, Makino H, Suganami T, Ogawa Y, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000;11:1691–701.PubMedGoogle Scholar
  48. Suganami T, Mukoyama M, Sugawara A, Mori K, Nagae T, Kasahara M, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol. 2001;12:2652–63.PubMedGoogle Scholar
  49. Makino H, Mukoyama M, Mori K, Suganami T, Kasahara M, Yahata K, et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia. 2006;49:2514–24.PubMedView ArticleGoogle Scholar
  50. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.PubMedView ArticleGoogle Scholar
  51. Vazquez-Rangel A, Soto V, Escalona M, Toledo RG, Castillo EA, Polanco Flores NA, et al. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;63:1072–4.PubMedView ArticleGoogle Scholar
  52. Kitamura S, Horimoto N, Tsuji K, Inoue A, Takiue K, Sugiyama H, et al. The selection of peritoneal mesothelial cells is important for cell therapy to prevent peritoneal fibrosis. Tissue Eng Part A. 2014;20:529–39.PubMedGoogle Scholar
  53. Nagappan R, Collins JF, Lee WT. Fungal peritonitis in continuous ambulatory peritoneal dialysis—the Auckland experience. Am J Kidney Dis. 1992;20:492–6.PubMedView ArticleGoogle Scholar
  54. Wang AY, Yu AW, Li PK, Lam PK, Leung CB, Lai KN, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis. 2000;36:1183–92.PubMedView ArticleGoogle Scholar
  55. Felgueiras J, del Peso G, Bajo A, Hevia C, Romero S, Celadilla O, et al. Risk of technique failure and death in fungal peritonitis is determined mainly by duration on peritoneal dialysis: single-center experience of 24 years. Adv Perit Dial. 2006;22:77–81.PubMedGoogle Scholar
  56. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.PubMedView ArticleGoogle Scholar
  57. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant. 1998;13:154–9.PubMedView ArticleGoogle Scholar
  58. Lee HY, Kim BS, Choi HY, Park HC, Kang SW, Choi KH, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton). 2003;8(Suppl 1):S33–9.View ArticleGoogle Scholar
  59. Gupta S, Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol. 2007;68:125–9.PubMedView ArticleGoogle Scholar
  60. Trigka K, Dousdampanis P, Chu M, Khan S, Ahmad M, Bargman JM, et al. Encapsulating peritoneal sclerosis: a single-center experience and review of the literature. Int Urol Nephrol. 2011;43:519–26.PubMedView ArticleGoogle Scholar
  61. Sorenson WG, Shahan TA, Simpson J. Cell wall preparations from environmental yeasts: effect on alveolar macrophage function in vitro. Ann Agric Environ Med. 1998;5:65–71.PubMedGoogle Scholar
  62. Mizuno M, Morgan BP. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2004;3:87–96.PubMedView ArticleGoogle Scholar
  63. Mizuno M. A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. Curr Med Chem. 2006;13:1707–17.PubMedView ArticleGoogle Scholar
  64. Mizuno M, Ito Y, Hepburn N, Mizuno T, Noda Y, Yuzawa Y, et al. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. J Immunol. 2009;183:1403–12.PubMedView ArticleGoogle Scholar
  65. Mizuno T, Mizuno M, Morgan BP, Noda Y, Yamada K, Okada N, et al. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant. 2011;26:1821–30.PubMedView ArticleGoogle Scholar
  66. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem. 1998;273:16828–35.PubMedView ArticleGoogle Scholar
  67. Kim H, Mizuno M, Furuhashi K, Katsuno T, Ozaki T, Yasuda K, et al. Rat adipose tissue-derived stem cells attenuate peritoneal injuries in rat zymosan-induced peritonitis accompanied by complement activation. Cytotherapy. 2014;16:357–68.PubMedView ArticleGoogle Scholar
  68. Mizuno M, Ito Y, Mizuno T, Harris CL, Suzuki Y, Okada N, et al. Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. Am J Physiol Renal Physiol. 2012;302:F1245–51.PubMedView ArticleGoogle Scholar
  69. Guo QY, Peng WX, Cheng HH, Ye RG, Lindholm B, Wang T. Hyaluronan preserves peritoneal membrane transport properties. Perit Dial Int. 2001;21:136–42.PubMedGoogle Scholar
  70. Wang T, Cheng HH, Liu SM, Wang Y, Wu JL, Peng WX, et al. Increased peritoneal membrane permeability is associated with abnormal peritoneal surface layer. Perit Dial Int. 2001;21(Suppl 3):S345–8.PubMedGoogle Scholar
  71. Chunming J, Miao Z, Cheng S, Nana T, Wei Z, Dongwei C, et al. Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model. Ren Fail. 2011;33:355–62.PubMedView ArticleGoogle Scholar
  72. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int. 2001;21:245–53.PubMedGoogle Scholar
  73. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, et al. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int. 2004;24:37–47.PubMedGoogle Scholar
  74. Flessner MF, Credit K, Richardson K, Potter R, Li X, He Z, et al. Peritoneal inflammation after twenty-week exposure to dialysis solution: effect of solution versus catheter-foreign body reaction. Perit Dial Int. 2010;30:284–93.PubMedView ArticleGoogle Scholar
  75. Zeltzer E, Klein O, Rashid G, Katz D, Korzets Z, Bernheim J. Intraperitoneal infusion of glucose-based dialysate in the rat—an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport. Perit Dial Int. 2000;20:656–61.PubMedGoogle Scholar
  76. Nakao A, Nakao K, Takatori Y, Kojo S, Inoue J, Akagi S, et al. Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy. Nephrol Dial Transplant. 2010;25:1479–88.PubMedView ArticleGoogle Scholar
  77. Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol. 2011;22:914–26.PubMedPubMed CentralView ArticleGoogle Scholar
  78. Wang J, Jiang ZP, Su N, Fan JJ, Ruan YP, Peng WX, et al. The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci. 2013;14:10369–82.PubMedPubMed CentralView ArticleGoogle Scholar
  79. Duan WJ, Yu X, Huang XR, Yu JW, Lan HY. Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro. Am J Pathol. 2014;184:2275–84.PubMedView ArticleGoogle Scholar
  80. Yu JW, Duan WJ, Huang XR, Meng XM, Yu XQ, Lan HY. MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis. Lab Invest. 2014;94:978–90.PubMedView ArticleGoogle Scholar
  81. Aroeira LS, Lara-Pezzi E, Loureiro J, Aguilera A, Ramírez-Huesca M, González-Mateo G, et al. Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol. 2009;20:582–92.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Loureiro J, Aguilera A, Selgas R, Sandoval P, Albar-Vizcaíno P, Pérez-Lozano ML, et al. Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol. 2011;22:1682–95.PubMedPubMed CentralView ArticleGoogle Scholar
  83. Loureiro J, Sandoval P, del Peso G, Gónzalez-Mateo G, Fernández-Millara V, Santamaria B, et al. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One. 2013;8:e61165.PubMedPubMed CentralView ArticleGoogle Scholar
  84. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol. 1995;47:287–91.PubMedView ArticleGoogle Scholar
  85. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z, et al. Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int. 2003;23:14–22.PubMedGoogle Scholar
  86. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int. 2003;64:887–96.PubMedView ArticleGoogle Scholar
  87. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65:1927–36.PubMedView ArticleGoogle Scholar
  88. Bozkurt D, Hur E, Ulkuden B, Sezak M, Nar H, Purclutepe O, et al. Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis? Perit Dial Int. 2009;29(Suppl 2):S202–5.PubMedGoogle Scholar
  89. Bozkurt D, Sipahi S, Cetin P, Hur E, Ozdemir O, Ertilav M, et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int. 2009;29(Suppl 2):S206–10.PubMedGoogle Scholar
  90. Ertilav M, Hur E, Bozkurt D, Sipahi S, Timur O, Sarsik B, et al. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology (Carlton). 2011;16:552–7.View ArticleGoogle Scholar
  91. Huddam B, Başaran M, Koçak G, Azak A, Yalçın F, Reyhan NH, et al. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis. Int Urol Nephrol. 2015;47:1423–8.PubMedView ArticleGoogle Scholar
  92. Komatsu H, Uchiyama K, Tsuchida M, Isoyama N, Matsumura M, Hara T, et al. Development of a peritoneal sclerosis rat model using a continuous-infusion pump. Perit Dial Int. 2008;28:641–7.PubMedGoogle Scholar
  93. Kanda R, Hamada C, Kaneko K, Nakano T, Wakabayashi K, Hara K, et al. Paracrine effects of transplanted mesothelial cells isolated from temperature-sensitive SV40 large T-antigen gene transgenic rats during peritoneal repair. Nephrol Dial Transplant. 2014;29:289–300.PubMedView ArticleGoogle Scholar
  94. Wakabayashi K, Hamada C, Kanda R, Nakano T, Io H, Horikoshi S, et al. Adipose-derived mesenchymal stem cells transplantation facilitate experimental peritoneal fibrosis repair by suppressing epithelial-mesenchymal transition. J Nephrol. 2014;27:507–14.PubMedView ArticleGoogle Scholar
  95. Saito H, Kitamoto M, Kato K, Liu N, Kitamura H, Uemura K, et al. Tissue factor and factor v involvement in rat peritoneal fibrosis. Perit Dial Int. 2009;29:340–51.PubMedGoogle Scholar
  96. Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, et al. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol. 2013;24:1627–42.PubMedPubMed CentralView ArticleGoogle Scholar
  97. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant. 2001;16:1262–6.PubMedView ArticleGoogle Scholar
  98. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res. 2002;46:505–10.PubMedView ArticleGoogle Scholar
  99. Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K, et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 2007;71:227–38.PubMedView ArticleGoogle Scholar
  100. Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H, et al. Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol. 2008;28:661–8.PubMedView ArticleGoogle Scholar
  101. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int. 2004;66:1677–85.PubMedView ArticleGoogle Scholar
  102. Nakav S, Kachko L, Vorobiov M, Rogachev B, Chaimovitz C, Zlotnik M, et al. Blocking adenosine A2A receptor reduces peritoneal fibrosis in two independent experimental models. Nephrol Dial Transplant. 2009;24:2392–9.PubMedView ArticleGoogle Scholar
  103. Kokubo S, Sakai N, Furuichi K, Toyama T, Kitajima S, Okumura T, et al. Activation of p38 mitogen-activated protein kinase promotes peritoneal fibrosis by regulating fibrocytes. Perit Dial Int. 2012;32:10–9.PubMedPubMed CentralView ArticleGoogle Scholar
  104. Yokoi H, Kasahara M, Mori K, Ogawa Y, Kuwabara T, Imamaki H, et al. Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosis. Kidney Int. 2012;81:160–9.PubMedView ArticleGoogle Scholar
  105. Nishino T, Ashida R, Obata Y, Furusu A, Abe K, Miyazaki M, et al. Involvement of lymphocyte infiltration in the progression of mouse peritoneal fibrosis model. Ren Fail. 2012;34:760–6.PubMedView ArticleGoogle Scholar
  106. Sekiguchi Y, Hamada C, Ro Y, Nakamoto H, Inaba M, Shimaoka T, et al. Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model. J Artif Organs. 2012;15:272–82.PubMedView ArticleGoogle Scholar
  107. Hirose M, Nishino T, Obata Y, Nakazawa M, Nakazawa Y, Furusu A, et al. 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model. Perit Dial Int. 2013;33:132–42.PubMedPubMed CentralView ArticleGoogle Scholar
  108. Yokoi H, Kasahara M, Mori K, Kuwabara T, Toda N, Yamada R, et al. Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-dideoxyglucosone-3-ene in mice. Perit Dial Int. 2013;33:143–54.PubMedPubMed CentralView ArticleGoogle Scholar
  109. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int. 2006;26:380–92.PubMedGoogle Scholar
  110. Hirahara I, Ishibashi Y, Kaname S, Kusano E, Fujita T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant. 2009;24:437–47.PubMedView ArticleGoogle Scholar
  111. Hirahara I, Sato H, Imai T, Onishi A, Morishita Y, Muto S, et al. Methylglyoxal induced basophilic spindle cells with podoplanin at the surface of peritoneum in rat peritoneal dialysis model. Biomed Res Int. 2015;2015:289751.Google Scholar
  112. Onishi A, Akimoto T, Morishita Y, Hirahara I, Inoue M, Kusano E, et al. Peritoneal fibrosis induced by intraperitoneal methylglyoxal injection: the role of concurrent renal dysfunction. Am J Nephrol. 2014;40:381–90.PubMedView ArticleGoogle Scholar
  113. Kitamura M, Nishino T, Obata Y, Furusu A, Hishikawa Y, Koji T, et al. Epigallocatechin gallate suppresses peritoneal fibrosis in mice. Chem Biol Interact. 2012;195:95–104.PubMedView ArticleGoogle Scholar
  114. Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, et al. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. Lab Invest. 2015;95:1029–43.PubMedView ArticleGoogle Scholar
  115. Liu L, Shi CX, Ghayur A, Zhang C, Su JY, Hoff CM, et al. Prolonged peritoneal gene expression using a helper-dependent adenovirus. Perit Dial Int. 2009;29:508–16.PubMedGoogle Scholar
  116. Patel P, Sekiguchi Y, Oh KH, Patterson SE, Kolb MR, Margetts PJ. Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney Int. 2010;77:319–28.PubMedView ArticleGoogle Scholar
  117. Margetts PJ, Hoff C, Liu L, Korstanje R, Walkin L, Summers A, et al. Transforming growth factor β-induced peritoneal fibrosis is mouse strain dependent. Nephrol Dial Transplant. 2013;28:2015–27.PubMedView ArticleGoogle Scholar
  118. Padwal M, Siddique I, Wu L, Tang K, Boivin F, Liu L, et al. Matrix metalloproteinase 9 is associated with peritoneal membrane solute transport and induces angiogenesis through β-catenin signaling. Nephrol Dial Transplant. 2016. doi:10.1093/ndt/qfw076.PubMedGoogle Scholar
  119. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol. 2001;12:2029–39.PubMedGoogle Scholar
  120. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2005;16:425–36.PubMedView ArticleGoogle Scholar
  121. Gotloib L, Wajsbrot V, Cuperman Y, Shostak A. Acute oxidative stress induces peritoneal hyperpermeability, mesothelial loss, and fibrosis. J Lab Clin Med. 2004;143:31–40.PubMedView ArticleGoogle Scholar
  122. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int. 1996;16:613–6.PubMedGoogle Scholar
  123. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis—role of acidic solution. Perit Dial Int. 2001;21(Suppl 3):S349–53.PubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement